These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 30224159)

  • 61. Nonmotor symptoms in Parkinson's disease: expanding the view of Parkinson's disease beyond a pure motor, pure dopaminergic problem.
    Sung VW; Nicholas AP
    Neurol Clin; 2013 Aug; 31(3 Suppl):S1-16. PubMed ID: 23931951
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dynamics of impulsive-compulsive behaviors in early Parkinson's disease: a prospective study.
    Marković V; Stanković I; Petrović I; Stojković T; Dragašević-Mišković N; Radovanović S; Svetel M; Stefanova E; Kostić V
    J Neurol; 2020 Apr; 267(4):1127-1136. PubMed ID: 31902006
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease.
    Sriram A; Ward HE; Hassan A; Iyer S; Foote KD; Rodriguez RL; McFarland NR; Okun MS
    J Neurol; 2013 Feb; 260(2):521-7. PubMed ID: 23007193
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Pathological gambling and Parkinson disease].
    Fujimoto K
    Brain Nerve; 2008 Sep; 60(9):1039-46. PubMed ID: 18807938
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Dopaminergic dysregulation syndrome in Parkinson's disease.
    Katzenschlager R
    J Neurol Sci; 2011 Nov; 310(1-2):271-5. PubMed ID: 21868039
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease.
    Fenu S; Wardas J; Morelli M
    Behav Pharmacol; 2009 Sep; 20(5-6):363-79. PubMed ID: 19724195
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Depression and impulse control disorders in Parkinson's disease: two sides of the same coin?
    Vriend C; Pattij T; van der Werf YD; Voorn P; Booij J; Rutten S; Berendse HW; van den Heuvel OA
    Neurosci Biobehav Rev; 2014 Jan; 38():60-71. PubMed ID: 24239733
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Impulse control and related disorders in Parkinson's disease.
    Vargas AP; Cardoso FEC
    Arq Neuropsiquiatr; 2018 Jun; 76(6):399-410. PubMed ID: 29972423
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Stocchi F
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S9-S15. PubMed ID: 19131046
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The mediating effects of depression, anxiety, and rapid eye movement sleep behavior disorder on the association between dopaminergic replacement therapy and impulse control disorders in Parkinson's disease.
    Du S; Huang Y; Ma Y; Qin Y; Cui J; Bai W; Han H; Zhang R; Yu H
    Neurol Sci; 2023 Feb; 44(2):557-564. PubMed ID: 36221041
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Prevalence of neuropsychiatric disorders in drug-naive subjects with Parkinson's disease (PD)].
    Isais-Millán S; Piña-Fuentes D; Guzmán-Astorga C; Cervantes-Arriaga A; Rodríguez-Violante M
    Gac Med Mex; 2016; 152(3):357-63. PubMed ID: 27335192
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease.
    Potenza MN; Voon V; Weintraub D
    Nat Clin Pract Neurol; 2007 Dec; 3(12):664-72. PubMed ID: 18046439
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Extrastriatal dopaminergic changes in Parkinson's disease patients with impulse control disorders.
    Lee JY; Seo SH; Kim YK; Yoo HB; Kim YE; Song IC; Lee JS; Jeon BS
    J Neurol Neurosurg Psychiatry; 2014 Jan; 85(1):23-30. PubMed ID: 24023269
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The role of dopamine pharmacotherapy and addiction-like behaviors in Parkinson's disease.
    Napier TC; Kirby A; Persons AL
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Aug; 102():109942. PubMed ID: 32272129
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The rise and fall of impulse control behavior disorders.
    Cossu G; Rinaldi R; Colosimo C
    Parkinsonism Relat Disord; 2018 Jan; 46 Suppl 1():S24-S29. PubMed ID: 28818561
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Suicide attempt in a dopamine agonist withdrawal syndrome in Parkinson's disease.
    Espindola M; Rojas NG; Vaisentein G; Da Prat G; Cesarini M; Etcheverry JL; Gatto EM
    Parkinsonism Relat Disord; 2024 Apr; 121():106017. PubMed ID: 38401377
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs.
    Poletti M; Logi C; Lucetti C; Del Dotto P; Baldacci F; Vergallo A; Ulivi M; Del Sarto S; Rossi G; Ceravolo R; Bonuccelli U
    J Clin Psychopharmacol; 2013 Oct; 33(5):691-4. PubMed ID: 23857310
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Molecular imaging and neural networks in impulse control disorders in Parkinson's disease.
    Aracil-Bolaños I; Strafella AP
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1(Suppl 1):S101-5. PubMed ID: 26298389
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hypomania and mania related to dopamine replacement therapy in Parkinson's disease.
    Maier F; Merkl J; Ellereit AL; Lewis CJ; Eggers C; Pedrosa DJ; Kalbe E; Kuhn J; Meyer TD; Zurowski M; Timmermann L
    Parkinsonism Relat Disord; 2014 Apr; 20(4):421-7. PubMed ID: 24467817
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Impulse control disorders, dopamine dysregulation syndrome and sex dysfunction in Parkinson's disease.
    Irincu L; Ivan I; Diaconu Ș; Falup-Pecurariu C
    Int Rev Neurobiol; 2022; 162():117-134. PubMed ID: 35397783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.